The UK’s National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug Leqembi due to cost-effectiveness concerns.

The U.K. regulatory authority approved the Alzheimer’s disease drug, Leqembi, last month. But the U.K. cost-effectiveness watchdog NICE recommends against reimbursement…

Read More: https://www.forbes.com/sites/joshuacohen/2024/09/02/uks-cost-effectiveness-watchdog-nice-says-no-to-alzheimers-drug-leqembi/